Objective: To evaluate the effectiveness of risperidone long-acting injection (RLAI) treatment on personal and social functioning in patients with schizophrenia enrolled in the electronic-Schizophrenia Treatment Adherence Registry (e-STAR) from six countries (Canada, Czech Republic, Denmark, Netherlands, Slovakia, Sweden) that collected Personal and Social Performance (PSP) data. Methods: e-STAR is an international, long-term, prospective, observational study of patients with schizophrenia who commence RLAI. Data are collected retrospectively for one year and prospectively every three months for two years. Personal and social functioning is measured using the PSP scale which evaluates four areas, socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviour. Pooled results presented are based on data from patients who have completed their six-month follow-up visit. Results: To date, 1831 are enrolled in e-STAR from the six countries, 1232 patients who have been followed for at least 6 months are included in this analysis. Mean age was 38.4±12.5 years, 58.6% were male and mean time since diagnosis was 9.6±11.6 years. At 6 months, 95.5% of patients are still on RLAI. The mean PSP score significantly improved from 48.0±17.3 at baseline to 64.2±15.2 at 6 months (p<0.001). Improvement in PSP was similar for patients hospitalized at baseline versus those who were ambulatory patients (PSP score increased by 17.2 and 16.1, respectively, p<0.001 for both). Furthermore, significant improvement in PSP was seen as soon as the first assessment after RLAI treatment at three months. Conclusion: These 6-month interim results indicate that personal and social functioning as measured by the PSP improved with risperidone long-acting injection treatment in patients with schizophrenia.